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Chemokines and chemokine receptors are involved in the reso- mon cause of end-stage renal failure, and this process
lution or progression of renal disease. Locally secreted chemo- correlates with progressive tubulointerstitial injury and
kines mediate leukocyte recruitment during the initiation and renal fibrosis [1–4]. Progressive interstitial fibrosis is char-amplification phase of renal inflammation. In turn, the infiltrat-
acterized by the accumulation of leukocytes, fibroblasts,ing leukocytes contribute to renal damage by releasing inflam-
extracellular fibrous matrix as well as tubular atrophy [5].matory and profibrotic factors. Rapid down modulation of the
chemokine signal will support resolution of acute inflammation, In this process the accumulation of interstitial leukocytes
whereas progression occurs if ongoing or repeated renal injury is critical for mediating fibroblast proliferation, differen-
maintains continuous local chemokine secretion and leukocyte
tiation into myofibroblasts, matrix production, and tubu-influx into the glomerulus or the interstitial space. In glomerular
lar damage as infiltrating macrophages and lymphocytesinjury proteinuria itself as well as glomerular secreted cytokines
stimulate downstream tubular epithelial cells to also secrete are major sources for proinflammatory and profibrotic
chemokines. During primary tubular injury, tubular epithelial cytokines [6]. Therefore, understanding the mechanisms
cells directly become a major site of chemokine production. that direct circulating leukocytes to and maintain them in
This in turn supports leukocyte infiltration and activation. In-
the interstitial space may offer new therapeutic targets offiltrating leukocytes stimulate fibroblast proliferation and ma-
progressive renal disease. In this context, the concertedtrix synthesis, leading to widening of the interstitial space. The
specific and intricate renal vascular architecture renders the interaction of chemokines and adhesion molecules have
organ susceptible to ischemic damage as interstitial volume been shown to play important roles not only in the con-
increases. Ischemia in turn serves as a stimulus for chemokine trol of leukocyte recruitment, activation, and effector func-and cytokine production and matrix synthesis. The mutual stim-
tion, but also in the modulation of angiogenesis and aspectsulation between fibroblasts and infiltrating leukocytes supports
of adaptive immunity [7–12]. As these diverse biologicprogressive tubular damage, renal fibrosis, and glomeruloscle-
rosis. Potentially this vicious circle leading to progression of processes are all involved in progressive renal disease and
chronic nephropathies offers the opportunity for therapeutic fibrosis, the chemokine system is a potential target for
intervention. Interfering with the chemokine network that me- therapeutic intervention. Previous reviews centered mostlydiates leukocyte recruitment may represent a promising thera-
on the role of chemokines in acute glomerular and inter-peutic option for progressive renal disorders and renal fibrosis.
stitial inflammation [reviewed in 8]. In view of the hy-This article summarizes the present data on the role of chemo-
kines in acute and chronic renal disease with special emphasis pothesis that blockade of leukocyte infiltration may be
on their potential role in mediating resolution or progression a valuable approach for the treatment of progressive
of renal disease as well as on therapeutic options.
renal disease, our current review focuses on the biology
of chemokines and chemokine receptors in the context
of resolution or progression of renal disorders. First, aProgression of the various nephropathies to end-stage
model of the role of chemokines in the various stagesrenal disease remains a major problem in nephrology as
of renal disease is presented. In the second part, the regu-only some renal diseases resolve after an acute phase
lation of resolution or progression and possible therapeu-whereas most tend to become chronic. The resulting slow
tic implications of chemokine blockade are discussed.but continuous decline of renal function is the most com-
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Fig. 1. Proposed model of chemokine involvement in progressive renal disease and fibrosis. Details are in the text.
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Initiation phase kines such as FGF-2 [17]. In addition, blood borne imma-
ture, monocyte-like cells, referred to as fibrocytes, rap-Injury to any type of renal parenchymal cells leads to
idly enter sites of tissue injury and contribute to the localthe secretion of proinflammatory mediators that induce
fibrosis [18]. However, their role in renal fibrosis has notleukocyte infiltration and activation at the place of injury
yet been determined.(Fig. 2A). If the inflammatory process is restricted either
Another common observation leading to interstitialto the glomerulus or to the tubulointerstitium the leuko-
fibrosis is the appearance of an interstitial cell infiltratecyte infiltration will be restricted to the respective com-
in primary glomerulopathies such as membranous GN,partment [13, 14]. The selective recruitment of certain
focal glomerulosclerosis or mesangioproliferative GN. Theleukocyte subsets to different compartments of the kid-
tubular epithelial cell may have an important role in medi-ney further illustrates the complexity of this process. For
ating the progression from glomerular to tubulointerstitialexample, except for transplant glomerulitis, T cells are
nephritis. Spillover of proinflammatory mediators, growthrarely found within the glomerular tuft as long as Bow-
factors, and even albumin into the glomerular ultrafil-man’s capsule is intact, whereas T cells are commonly
trate appear as stimulators for tubular epithelial cells topresent in interstitial infiltrates [15]. Compared to peritu-
secrete additional proinflammatory profibrotic cytokinesbular vessels glomerular capillaries may not support the
and chemokines [8]. Furthermore, proinflammatory me-binding and transmigration of T cells, a phenomenon that
diators secreted within the glomerulus will reach thecould be related to a different expression of adhesion
post-glomerular peritubular circulation, thereby activat-molecules and chemokines or simply to higher shear stress
ing peritubular endothelial and tubular epithelial cellsin the glomerular microcirculation. On the other hand,
[19]. In addition, focal capsular adhesions develop “mis-macrophages can be found intraglomerularly during pro-
directed” ultrafiltrate that may result in local generationliferative and especially crescentic glomerulonephritis.
of mediators [20]. All of these mechanisms may enhanceMicrothrombosis of glomerular capillaries, which is com-
interstitial mononuclear cell recruitment secondary tomonly present in focal necrotic or crescentic lesions, may
primary glomerular injury and thus expand the lesioncontribute to this phenomenon.
from the glomerulus to the tubulointerstitium.
Amplification phase Progression phase
Infiltration and local proliferation of leukocytes further The continuous stimulation of intrinsic renal paren-
enhance the local production of cytokines and chemokines chymal cells by infiltrating leukocytes, proteinuria, and
(Fig. 2B). Furthermore, neutrophils and macrophages gen- secreted cytokines results in ongoing synthesis of extra-
erate radical oxygen species and lipid mediators that con- cellular matrix components and irreversible structural
tribute to local tissue damage, supporting positive feed- damage (Fig. 2C). In the glomerulus infiltrating macro-
back mechanisms. Macrophages themselves may secrete phages stimulate mesangial cells to secrete collagen type
extracellular matrix components, but they also are the IV, laminin, and fibronectin that contribute to the devel-
major source of growth factors such as fibroblast growth opment of glomerulosclerosis [21]. Mesangial expansion
factor (FGF), transforming growth factor- (TGF-), also leads to narrowing or obliteration of single glomeru-
tumor necrosis factor- (TNF-), epithelial growth fac- lar capillaries as well as dilation of others [22]. Eventually
tor (EGF), and platelet-derived growth factor (PDGF) this will not only result in podocyte damage and glomeru-
[6]. These cytokines stimulate mesangial cell prolifera- lar sclerosis, but also in destruction of the entire nephron,
tion and matrix synthesis in the glomerulus leading to including downstream peritubular capillaries [20, 22].
the typical pictures of mesangioproliferative glomerulo- Thus, the tubulointerstitial compartment undergoes ma-
nephritis (GN) [16]. Activation of podocytes leads to jor structural rearrangement. The accumulation of T cells
rearrangement of the complex secondary structure, in- and macrophages provides continuous release of profi-
cluding the slit membrane leading to foot process efface- brotic mediators that induce the accumulation of fibro-
ment and proteinuria. Extensive podocyte damage leads blasts, and the ongoing production of extracellular matrix.
to focal adhesions of the denuded GBM to Bowman’s Activated tubular epithelial cells themselves contribute
capsule and to focal glomerulosclerosis. to this phenomenon by matrix production chemokine-
In the tubulointerstitium, fibroblast proliferation and cytokine release, and even to transdifferentiate to myo-
secretion of extracellular matrix leads to widening of the fibroblasts that migrate into the interstitial space [17].
interstitial space and renal fibrogenesis. Sources of the The interstitial cell infiltrate itself, together with the in-
heterogeneous fibroblast population include prolifera- creasing amount of extracellular matrix, lead to critical
tion of resident fibroblasts and myofibroblasts derived widening of the interstitial space, thereby increasing the
from tubular epithelial cells by a process described as distance of the remaining peritubular capillaries to their
epithelial-mesenchymal transformation, two mechanisms respective tubular segments, impairing oxygen diffusion
as well as tubular reabsorption and excretory functionthat are induced by macrophage derived profibrotic cyto-
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Fig. 2. (A) Initiation phase. All types of in-
trinsic renal cells can secrete chemokines as
a response to immunologic, toxic, ischemic or
mechanical injury ( ). The selective expres-
sion of adhesion molecules and chemokines
on endothelial cells of glomerular or peritubu-
lar capillaries supports leukocyte arrest and
transmigration either into the mesangium or
the interstitial space. (B) Amplification phase.
As long as the initial stimulus persists, infil-
trating leukocytes release lipid mediators, cyto-
kines, and chemokines, leading to glomerular
and/or tubulointerstitial inflammation, which
results in hematuria, leukocyturia, and protein-
uria. Proinflammatory and profibrotic cyto-
kines stimulate the proliferation of mesangial
cells in the glomerulus and of interstitial fibro-
blasts in the interstitium. Upon stimulation
activated mesangial cells and interstitial fibro-
blasts increase the synthesis of extracellular ma-
trix components. Leukocyte infiltration, fibro-
blast proliferation, matrix deposition as well
as edema will increase the interstitial volume.
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Fig. 2. (Continued) (C ) Progression phase.
Although the initial stimulus may have al-
ready subsided, the structural damage of acute
inflammation may have become irreversible.
Focal glomerulosclerosis with misdirected fil-
tration and proteinuria maintains a persistent
signal for tubular epithelial cells to release
chemokines into the interstitium. Overspill of
locally secreted cytokines and chemokines
also supports downstream inflammation of the
renal interstitium. Massive increase of the in-
terstitial volume and destruction of peritubu-
lar capillaries supports renal ischemia leading
to tubular atrophy, secondary glomeruloscle-
rosis, and progressive renal dysfunction. (D)
Terminal phase. Continuous destruction of
the peritubular capillary network and tubu-
lar segments further support renal ischemia,
which is a strong stimulus for fibroblast prolif-
eration and matrix synthesis via autocrine
mechanisms. Myofibroblasts support tissue
contraction up to the ultimate stage, the end-
stage shrunken kidney.
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Table 1. Chemokines and chemokine receptors
Ligand Receptors Function Ligand Receptors Function
CCL1 I-309 CCR8 i CXCL1 Gro CXCR1,2 i
CCL2 MCP-1 CCR2 i CXCL2 Gro i
CCL3 MIP-1 CCR1,5 i CXCL3 Gro i
CCL4 MIP-1 CCR5 i CXCL4 PF4 CXCR1,2 i
CCL5 RANTES CCR1,3,5 i CXCL5 ENA-78 CXCR2 i
CCL7 MCP-3 CCR1,2 i CXCL6 GCP-2 CXCR1,2 i
CCL8 MCP-2 CCR1,2,5 i CXCL7 NAP-2 CXCR2 i
CCL11 Eotaxin CCR3 i CXCL8 IL-8 CXCR1,2 i
CCL13 MCP-4 CCR1,2,3 i CXCL9 Mig CXCR3 i
CCL14 HCC-1 CCR1 i CXCL10 IP-10 CXCR3 i
CCL15 HCC-2 CCR1 i CXCL11 I-TAC CXCR3
CCL16 HCC-4 CCR1,8 i CXCL12 SDF-1 CXCR4 h
CCL17 TARC CCR4 i CXCL13 BCA-1 CXCR5
CCL18 DC-CK1 CXCL14 Bolekine
CCL19 ELC CCR7 h CXCL15 Lungkine h
CCL20 LARC CCR6
CCL21 SLC/6Ckine CCR7 h XCL
CCL22 MDC CCR4 i XCL1 lymphotactin XCR1 i
CCL23 MPIF-1 CCR1 XCL2 SCM-1 i
CCL24 Eotaxin-2 CCR3 i
CCL25 TECK CCR9 i
CCL26 Eotaxin-3 CCR3 i CX3CL
CCL27 CTAK/Eskine CCR10 CX3CL1 Fractalkine CX3CR1 h,i
Abbreviations are: h, homeostatic, i, inflammatory.
[23]. The tubulointerstitial ischemia is considered to be scribed (Table 1). The chemokine superfamily can be
an important factor for tubular cell apoptosis, necrosis, divided into four branches (C, CC, CXC, and CX3C),
and, finally, tubular atrophy [24, 25]. Thus, progressive based upon the position of the first two cysteine residues
glomerular and interstitial injuries are tightly linked and in a four-cysteine motif in their primary amino acid se-
aggravate each other by multiple mechanisms, including quence [reviewed in 29]. These cysteines can be sepa-
ischemia. rated by one or three additional amino acids (designated
as X). The official nomenclature used to describe individ-
Terminal phase ual chemokines is based upon the class it belongs to, for
Finally, vascular rarification and diffuse scarring lead example, CC, CXC, CX3C, and C chemokines [28]. A
to extensive tubular atrophy, and glomerulosclerosis (Fig. subgroup of CXC chemokines displays the additional
2D). The extensive loss of renal parenchyma and struc- amino acid motif E-L-R-CXC (glutamic acid-leucine-
tural integrity finally results in end-stage renal disease arginine-cysteine-X-cysteine). The E-L-R-CXC chemo-
with the clinical signs and symptoms of uremia. Leuko- kines generally act as neutrophil chemoattractants and
cytic cell infiltrates resolve, but renal fibroblasts maintain promotors of angiogenesis, while the CXC chemokines
the synthesis of extracellular matrix due to sustained without the E-L-R motif bind to different receptors, are
hypoxia and autocrine stimulation [26, 27]. Myofibro- more active on lymphocytes, and inhibit angiogenesis.
blasts contribute to contraction of the fibrous tissue with Lymphotactin- and - are the only C chemokines de-
scarring, resulting in the ultimate stage, the shrunken scribed. They share homology with CC chemokines at
kidney. their carboxyl end, but lack the first and third cysteines in
In the above process there are roles for chemokines the four-cysteine motif [30]. Fractalkine, the only known
at multiple steps. The contribution of the chemokines
CX3C chemokine, has three additional amino acids be-cannot be viewed in isolation, but as part of an integral
tween the first two cysteine residues. It is tethered di-system together with adhesion molecules and cytokines.
rectly to the cell membrane via a mucin stalk and com-
bines the function of a chemokine and adhesion molecule
STRUCTURAL AND FUNCTIONAL [31]. By the new systematic nomenclature, chemokines
CLASSIFICATION OF CHEMOKINES AND are classified by the above criteria and their binding
CHEMOKINE RECEPTORS characteristics as ligands (L), such as, CL, CCL, CXCL
and CX3CL.Chemokines are low molecular weight cytokines that
Chemokines can be further classified according towere first characterized by their ability to induce directed
function and regulation of expression as inflammatorymigration of leukocytes [28]. To date, more than 44 che-
mokines and 21 chemokine receptors have been de- or homeostatic [10, 31]. The inflammatory chemokines
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are up-regulated by proinflammatory stimuli and orches- express both chemokine receptors CCR1 and CCR5,
which share the ligand CCL5/RANTES [36]. In an in vitrotrate innate and adaptive immune responses, such as
regulators of T cell differentiation [32]. The homeostatic system it was found that immobilized CCL5/RANTES
(regulated upon activation, normal T cell expressed andgroup of chemokines modulates lymphocyte and den-
dritic cell trafficking during immune surveillance [33]. secreted) induced leukocyte arrest via CCR1, while leu-
kocyte spreading was mediated via CCR5, and trans-All members of the chemokine family work in concert
with selectins and integrins to sort and direct effector endothelial migration was supported by both receptors
[36]. In this context it is of interest that chemokinesleukocyte migration [29, 34]. In addition chemokines
have been shown to play important roles in the control also modulate the redistribution of junctional adhesion
molecules (JAMs) of endothelial cell tight junctions thatof leukocyte activation and effector function.
The biologic action of chemokines is mediated through may promote leukocyte diapedesis by transient opening
of focal cell-cell contacts [37]. Furthermore, chemokinesa large family of seven-transmembrane-spanning G pro-
tein-coupled receptors [7, 10, 12]. Chemokine receptors such as CCL5/RANTES up-regulate the secretion and
activity of matrix metalloproteinases by infiltrating leu-are designated according to the class of the chemokine
ligands they bind, for example, CR, CCR, CXCR, and kocytes [38], thus facilitating leukocyte transmigration
through the basement membrane and extracellular ma-CX3CR. Each chemokine receptor has a distinct chemo-
kine specificity and a restricted expression on subclasses trix [39]. Chemokines such as CXCL8/IL8 also activate
infiltrating leukocytes inducing granule release and respi-of leukocytes and non-hematopoietic cells. However, the
ligand specificities of the receptors can substantially ratory burst [40, 41]. Finally, CCL5/RANTES can func-
tion as a co-stimulatory agent in T cell proliferation [42],overlap within a chemokine class leading to a high degree
of redundancy. Some receptors bind multiple chemo- so that chemokines are involved in multiple steps from
adhesion, transmigration, and activation to local prolifer-kines, and some chemokine ligands bind to multiple re-
ceptors [reviewed in 29, 31]. In general, the proinflam- ation of leukocytes at the site of tissue injury.
matory chemokine receptors have more promiscuous
ligand binding specificities, while receptors involved in CHEMOKINES MEDIATE RENAL
normal leukocyte trafficking have fewer ligands. In addi- INFLAMMATION DURING THE
tion, it has been proposed that some chemokine recep- INITIATION AND AMPLIFICATION PHASE
tors form homo- or heterodimers that may alter their
In vitro studiesfunction or sensitivity to chemokine stimulation [re-
All types of renal cells (that is, endothelial, mesangial,viewed in 29, 31].
tubular epithelial, interstitial cells, and podocytes) can
express chemokines upon stimulation in vitro [reviewed
CHEMOKINES MEDIATE LEUKOCYTE in 8]. In general, proinflammatory stimuli such as TNF-,
TRAFFICKING AT MULTIPLE STAGES interleukin-1 (IL-1) interferon- (IFN-), and lipo-
Chemokines mediate events at multiple stages in the polysaccharide (LPS) rapidly induce CCL2/MCP-1, CXL8/
process of leukocyte-endothelium interaction and trans- IL-8, and CXCL10/IP-10 within few hours. CCL5/RANTES
migration [8, 31]. Injured renal cells produce chemokines is induced in a more delayed manner after 12 to 48 hours
and many other inflammatory cytokines. This in turn en- [8]. Reactive oxygen species generation may represent
hances the expression of adhesion molecules on endothe- a common mechanism of injury-induced chemokine gen-
lial cells. As an early event reversible rolling of leukocytes eration [43]. Growth factors and vasoactive agents like
along the endothelial surface occurs through transient in- angiotensin II also may stimulate chemokine production
teractions between selectins and vascular addressins. of certain cell types (for example, endothelial cells) [44].
Rolling leukocytes are brought into contact with chemo- Furthermore, immune complexes and complement acti-
kines, which are retained on heparan sulfate proteogly- vation cause mesangial production of chemokines [8],
cans of the endothelial surface following secretion by, and in proximal tubular cells chemokines can be induced
for example, activated endothelial cells or subendothelial by high concentrations of albumin [45, 46].
renal cells. The chemokines bind to the respective che-
Descriptive in vivo studiesmokine receptors of the rolling leukocytes and thereby
activate leukocyte-expressed integrins, resulting in shear- Several studies have characterized the expression pat-
resistant firm adhesion of the leukocyte to the endothe- terns of the chemokines in animal models of acute glo-
lial surface as a prerequisite for leukocyte emigration merular or tubulointerstitial disease. They demonstrated
[31, 34]. Specific but apparently redundant chemokines that various inflammatory chemokines such as CCL2/
appear to differentially influence spreading, diapedesis, monocyte chemoattractant protein-1 (MCP-1), CCL3/
and subsequent migration into the tissue space [31, 35]. MIP-1, CCL4/MIP-1, and CCL5/RANTES are expressed
only in the diseased compartment of the kidney [reviewedFor example, monocytes and T helper-1 (Th1)-like T cells
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in 8]. Renal chemokine expression has been found to In this model tubular CCL2/MCP-1 expression was more
prominent than glomerular expression, which may ex-correlate with the local accumulation of leukocytic ef-
fector cells and renal damage. The Duffy antigen recep- plain the localized effect [59]. A similar reduction of
tubulointerstitial damage was obtained with a CCL2/tor for chemokines (DARC) binds multiple chemokines
including CCL5/RANTES, but lacks signaling function. MCP-1 antisense approach in rats with nephrotoxic se-
rum nephritis [60]. A role of CX3CL1/fractalkine in medi-In the normal kidney DARC is only and is expressed
on post-capillary venules [47]. During various forms of ating renal leukocyte infiltration and inflammatory injury
was demonstrated recently. Treatment with a neutraliz-renal diseases DARC expression expands to most peritu-
bular vessel endothelium [47]. DARC might serve as an ing antibody against the CX3CL1/fractalkine receptor
CX3CR1 improved renal function and prevented cres-endothelial presentation molecule for chemokines in-
volved in signaling of specific exit sites for chemokine centic glomerulonephritis in the rat nephrotoxic serum
nephritis model [61]. Using the CCL5/RANTES antago-positive cells into the interstitium.
The relevance of the animal data for human disease nist Met-RANTES Lloyd et al showed in nephrotoxic
serum nephritis that mice treated with Met-RANTES hadhas been confirmed by a variety of human biopsy studies
that have analyzed the chemokine expression patterns in reduced proteinuria, T cell, and macrophage infiltration
[58]. The CCL5/RANTES antagonist AOP-RANTES in-renal diseases [reviewed in 8]. Local expression of chemo-
kines also may contribute to another common observation hibited glomerular macrophage infiltration and collagen
IV deposition in the anti-Thy-1.1 model [62]. A virus-made during active GN, that is, the periglomerular accu-
mulation of macrophages and T cells. Immunohistological derived antagonist blocking multiple chemokine recep-
tors, vMIP-2, decreased proteinuria and interstitial leuko-and in situ hybridization studies have demonstrated che-
mokine expression by parietal glomerular epithelial cells cyte infiltration in rat nephrotoxic serum nephritis [63].
These rat and mouse studies in different models of glomer-[48–50]. The release of chemokines by these cells into
the surrounding interstitium may facilitate the periglom- ular injury would support roles for CCL5/RANTES and
CCL2/MCP-1 in the initiation of the leukocyte influx anderular accumulation of leukocytes.
Besides intrinsic renal cells, infiltrating leukocytes be- the resulting proteinuria (abstract; Pi et al, J Am Soc
Nephrol 12:A4608, 2001). Surprisingly, however, studiescome a major source of local chemokine production in a
positive amplification loop [13, 14]. Chemokines secreted with mice with deletions of the genes encoding for these
chemokines or their receptors have yielded partially con-during the initiation phase of injury also may target in-
trinsic renal cells. The local production of CXCL10/IP-10 flicting results [59, 64–66]. For example, mice with tar-
geted gene deletion of CCL2/MCP-1 had reduced inter-could induce proliferation of mesangial cells presumably
via the CXCR3 receptor [51]. CCR7, the receptor for stitial leukocyte infiltration and tubular injury during the
nephrotoxic serum nephritis [59]. However, glomerularCCL19/ELC and CCL21/SLC is expressed on mesangial
cells and mediates proliferative and anti-apoptotic ef- histopathology was not affected, which may relate to the
particular glomerular lesions of the nephrotoxic serumfects [52]. The functional role of CCR1 expression by
mesangial cells upon stimulation by CCL5/RANTES re- model in mice that lack major glomerular macrophage
infiltration [60, 67]. However, another group found amains to be elucidated [53].
marked reduction of crescent formation with a CCL2/
Functional studies in animal models of renal diseases MCP-1 blocking antibody in this model [58]. In mice
lacking the CCR2 receptor for CCL2/MCP-1 renal pa-The role of chemokines in the pathogenesis of renal
inflammation was examined by blocking chemokine ac- thology after nephrotoxic serum was worse despite re-
duced glomerular macrophage infiltration, indicating thattivity with neutralizing antibodies, chemokine receptor
antagonists, and targeted disruption of genes encoding lack of CCR2 may influence other immune mechanisms
besides the local cell infiltration [64]. Conflicting resultschemokines and their receptors in various animal models
[8, 54]. These studies yield in part conflicting results also were obtained with chemokine receptor antagonists
and knockout mice for the chemokine receptors CCR1concerning the role of chemokines illustrating the multi-
faceted role of these mediators. For example, neutraliz- and CXCR3 with this model [58, 61, 66]. Although inter-
pretation of data derived from the nephrotoxic seruming antibodies against CCL2/MCP-1 reduced infiltration
of glomerular macrophages in rat anti-Thy-1.1 nephritis nephritis model is often difficult due to different prepara-
tions of nephrotoxic antisera and the different mouse[55]. Treatment with anti-CCL2/MCP-1 antibodies re-
duced proteinuria and monocyte influx in rat nephro- strains used [67–69], the reasons for the discrepant results
with antagonist, blocking antibodies, and knockout micetoxic serum nephritis [56, 57] and abrogated crescent
formation and leukocyte infiltration in murine nephro- remain unclear. In the case of mutant mice they could
involve the development of compensatory chemokine andtoxic nephritis [58]. However, in CCL2/MCP-1 deficient
mice given nephrotoxic serum the glomerular injury per- receptor systems or alterations in the immune response.
The latter could occur also with the use of chemokinesisted while the tubulointerstitial injury was reduced [59].
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antagonists and blocking antibodies. Potential immune fibrosis [14, 77, 78]. In areas of interstitial fibrosis CCL5/
modulation secondary manipulating the chemokine sys- RANTES is predominantly expressed by leukocytes but
tem is discussed later in this review. may be secreted also by interstitial fibroblasts [14, 77].
In summary, a wealth of data demonstrates the expres- Consequently, CCR5-positive lymphocytes accumulate
sion of chemokines in renal inflammation and tissue dam- in the interstitium and the amount of interstitial CCR5
age. Despite considerable in vitro redundancy of che- positive lymphocytes has been found to correlate with
mokine-chemokine receptor interaction, in vivo specific serum creatinine levels in human biopsies of various
chemokines can mediate unique and relevant effects. How- renal disorders [15]. Although diabetic and vascular ne-
ever, at present conflicting results with chemokine antag- phropathies are two major causes of progressive renal
onists and chemokine receptor knockout mice in models disease, only a few studies have been published on the
of acute renal inflammation do not allow a simplistic antic- role of chemokines in these disorders. An increased ex-
hemotactic approach to the therapy of acute inflamma- pression of CCL2/MCP-1 was reported in human diabetic
tory renal disorders [54]. More in depth studies on poten- nephropathy that correlated with the degree of tubulo-
tial systemic immunmodulatory effects of disruption of interstitial damage and macrophage infiltration [79–81].
specific chemokines and their receptors will be required In angiotensin II-dependent rat models of hypertensive
prior to the design of therapeutic trials with chemokine nephrosclerosis CCL2/MCP-1 expression was increased
antagonists. and was temporally and spatially related to macrophage
infiltration [82].
CHEMOKINES MEDIATE INFLAMMATION
Functional studies in animal models and in patientsDURING THE PROGRESSION OF
with renal diseasesRENAL DISEASES
The functional role of chemokines in interstitial dis-In vitro studies
ease was confirmed by several animal studies using che-
Tubulointerstitial leukocyte recruitment and activa- mokine antagonists or chemokine-deficient mice. Anti-
tion depends on chemokine-mediated processes and CCL2/MCP-1 antiserum reduced interstitial leukocyte
interstitial fibroblasts will produce chemokines during infiltrates and interstitial collagen deposition in mice
hypoxia, hyperglycemia and upon stimulation with pro- with nephrotoxic serum nephritis [58]. As mentioned be-
inflammatory cytokines [8, 70–73]. In turn, chemokines fore, CCL2/MCP-1 knockout-mice with nephrotoxic ne-
may directly mediate profibrogenic effects through re-
phritis develop less severe tubulointerstitial damage [59].ceptors on parenchymal cells. For example, CCL2/MCP-1
We and others have shown that several CC-chemokinescan increase collagen mRNA levels in cultured fibro-
and osteopontin are expressed in increasing amountsblasts [74], and CCR2 and CXCR2 expression has been
within the tubulointerstitium after unilateral ureter liga-reported for pulmonary and dermal fibroblasts, respec-
tion [14, 83, 84]. We have recently shown that CCR1tively [75, 76]. At present it remains unclear if renal
blockade substantially reduced interstitial leukocyte in-fibroblasts express chemokine receptors. So far, immu-
filtration, interstitial fibroblast accumulation, collagennohistological and in situ hybridization studies of human
deposition, and interstitial fibrosis after ureter obstruc-biopsies have not found expression of CCR2, CCR5 or
tion [85]. The MRL/MpJ Faslpr/lpr (MRL/lpr) mouse, whichCXCR4 on intrinsic renal cells, including fibroblasts. Other
serves as a model of systemic lupus, develops a chronicchemokine receptors have not been tested to date, so
progressive immune complex nephritis [77]. In this modelthe question of the presence of chemokine receptors on
inflammation and chemokine expression is initially re-renal fibroblasts and their potential function remains
stricted to the glomerulus. Following the onset of pro-open at this point. On the other hand, in vitro studies
teinuria mice show increased expression of chemokinessuggest that activated renal fibroblasts could secrete che-
in peritubular lesions that correlated with progressivemokines like CCL2/MCP-1 and CXCL1/MIP-2 (abstract;
mononuclear cell infiltration and expression of chemo-Garcia et al, J Am Soc Nephrol 12:630A, 2001), which in
kine receptors CCR1, CCR2, and CCR5 [77]. When CCL2/turn may attract further leukocytes secreting profibrotic
MCP-1–deficient knockout mice were crossbred withcytokines. As renal fibroblasts produce interstitial matrix
MRL/lpr mice, CCL2/MCP-1 deficiency reduced pro-components including collagen I upon the stimulation by
teinuria, renal damage and renal macrophage and T cellactivated macrophages, this indicates that chemokines,
recruitment but not proliferation [86]. This suggests thateither directly or indirectly via macrophage recruitment,
CCL2/MCP-1, presumably via its receptor CCR2, playscontribute to interstitial collagen deposition and fibrosis.
an important role in the leukocyte infiltration and re-
Descriptive studies in animal models of renal disease sulting tissue injury in the lupus model. Further support
and human renal biopsies of this hypothesis comes from human studies in patients
with lupus nephritis where urinary CCL2/MCP-1 levelsCCL2/MCP-1 is expressed by tubular epithelial cells
in animal models of progressive nephropathies and renal correlated with the extent of renal disease activity and
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macrophage infiltration [87, 88]. Furthermore, glucocor- found in interstitial cell infiltrates of human renal trans-
plants [15], these data may be relevant to human trans-ticoid treatment of the lupus nephritis resulted in a
prompt reduction in urinary CCL2/MCP-1 levels consis- plant rejection also. The strongest support for this hypoth-
esis comes from a recent multicenter case control studytent with in vitro results on the inhibitory effect of gluco-
corticoids on renal cell production of CCL2/MCP-1 [89]. in human renal transplant recipients [100]. In humans
a 32 bp deletion (32) in the CCR5 gene generates aA link may exist also between angiotensin II and che-
mokines in renal disease [90]. Blockade of the renin- nonfunctional receptor, which in the homozygous state
shows a prevalence of about 1% in the Caucasian popula-angiotensin system is currently the mainstay of treatment
for progressive renal disease. In this context it is interest- tion. The 32 homozygotes show no phenotype and rep-
resent essentially a CCR5 “knockout” population. Thising that enalapril and losartan reduced renal chemokine
expression in MRL/lpr mice in correlation with improved population was discovered as the lack of CCR5 protects
from infection with M-tropic HIV, which uses CCR5 asrenal function and renal damage (Perez de Lema, manu-
script submitted for publication). Renal MCP-1 expres- a coreceptor [101]. As in chronic transplant rejection
ligands for CCR5 are up-regulated, and the graft is infil-sion was reduced with angiotensin blockade in the dia-
betic rat, during rat immune complex glomerulonephritis, trated by CCR5-positive mononuclear cells, the influ-
ence of the 32 mutation of CCR5 was analyzed retro-the anti-Thy1.1 model, and after unilateral ureter liga-
tion [91–94]. spectively in renal transplants [100]. Out of over 1200
recipients of renal transplants, 21 (1.7%) were identifiedIn summary, these findings point toward a role for
chemokines and their receptors in leukocyte-mediated as homozygous for the CCR532 mutation. Graft survival
was significantly better in the homozygous32CCR5 groupprogressive tubulointerstitial damage and fibrosis, which
ultimately leads to end-stage renal disease. Conversely, compared to either heterozygote or wild-type transplant
recipients, suggesting a pathophysiological role for CCR5blockade of tubulointerstitial leukocyte recruitment and
activation by antagonism of chemokine actions may miti- in transplant loss [100]. A detailed analysis of various
chemokine receptor polymorphisms on the frequency ofgate chronic renal inflammation and subsequent fibrosis,
a hypothesis deserving further evaluation. acute rejection episodes of human renal transplants was
reported in a recent study [102]. Because of the smaller
number of patients examined no homozygotes for theCHEMOKINE INVOLVEMENT IN ACUTE AND
CCR532 mutation were present. However, evaluationCHRONIC TRANSPLANT REJECTION
of another mutation of CCR5 (homozygous for the
Expression of inflammatory chemokines, including 59029-A allele) as well as the CCR2 deletion (CCR2-
CCL5/RANTES, CCL2/MCP-1, CXCL10/IP-10, and XCL1/ 64I allele) significantly reduced the frequency of acute
lymphotactin, increases during acute and chronic allo- rejection episodes.
graft rejection [31]. In a rabbit model of acute renal al- Therefore, CCR5-mediated leukocyte influx and acti-
lograft rejection renal function and tubulointerstitial vation may be operational not only in acute transplant
damage improved when CCR1 was blocked with the small rejection, but also in chronic transplant survival. Thus,
peptide antagonist BX471 [95]. Blockade of the chemo- CCR5 may be a reasonable target for therapeutic inter-
kine receptor CXCR3 (binding CXCL9/Mig, CXCL10/ vention, especially as the absence of CCR5 in humans
IP-10, and CXCL11/I-TAC) and the CX3CL1/fractal- is not associated with any deleterious phenotype. Fur-
kine receptor CX3CR1 by neutralizing antibodies led to thermore, CCR5 may be a therapeutic target for non-
prolonged allograft survival in murine heart transplanta- transplant-related progressive nephropathies
tion models [96, 97], but their role in renal allograft
rejection has not yet been evaluated. In rat models of
CHEMOKINES CAN BE INVOLVED INacute renal allograft rejection treatment with the CCL5/
RESOLUTION OR PROGRESSION OFRANTES antagonist Met-RANTES, which blocks the
RENAL DISEASECCL5/RANTES receptors CCR1 and CCR5, significantly
reduced the vascular and tubular damage and suppressed Persistent exposure to triggers of renal injury is an
important factor for disease progression while removingmononuclear cell infiltration associated with acute rejec-
tion [98]. These results were confirmed and expanded triggers may eventually result in resolution of the in-
flammatory response with restoration of normal renalon in a recent study where application of Met-RANTES
for seven days after renal transplantation in rats improved architecture and function. Unfortunately, renal damage,
once established, has a tendency to progress even if thechronic transplant function with reduced proteinuria,
glomerulosclerosis, and interstitial fibrosis after 28 weeks, initial insult has subsided. What then could be the mecha-
nisms that determine either the resolution or the progres-supporting a role for chemokine antagonism for preven-
tion of chronic transplant loss [99]. As leukocytes express- sion of renal disease, and what role might chemokines
play in influencing the outcome?ing the CCL5/RANTES receptor CCR5 are frequently
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To date the mechanisms that control resolution or per- ease process. This was associated with increased chemo-
kine and chemokine receptor expression in the diseasedsistence of a leukocytic infiltrate in the kidney have not
been elucidated. Clearly, the normal glomerular architec- kidneys [Anders et al, J Am Soc Nephrol 2003 (in press)].
Thus, even if the triggering injury subsides, the renalture can be completely restored despite marked macro-
phage infiltration and mesangial hypercellularity during chemokine expression can be maintained by other mech-
anisms such as infection, renin-angiotensin activation,the active phase of immune complex glomerulonephritis
[103]. In this context it may be of interest that in a model hypoxia or proteinuria, and contribute to persistent leu-
kocyte infiltration and tissue damage.of transient immune complex glomerulonephritis, CCL2/
MCP-1 and CCL5/RANTES were up-regulated in the An essential factor in the switch between resolution
and progression may be the extent of irreversibly dam-early initiation phase but were already down-regulated
at the phase of maximal proteinuria and glomerular mac- aged renal architecture, which in turn depends on the
pattern of renal injury. Diffuse disease processes haverophage infiltration [13]. In addition to the transient ex-
pression of chemokines by most cell types in vitro, the a greater potential to induce progressive renal disease
compared to focal renal injury. If the nephron integritydown-regulation of chemokine synthesis by locally gen-
erated factors such as prostaglandins, TGF-, or induc- is destroyed, this may result in threatened tissue homeo-
stasis with cellular stress (hypoxic, mechanical, meta-tion of leukocyte apoptosis may terminate chemotactic
signaling in vivo [103–106]. During acute disease states, bolic, nutritional), turning into inflammation with ongo-
ing immune responses such as fibrosis and, thus, resultingtermination of the trigger injury therefore correlates with
a reduction of chemokine expression by intrinsic renal in a vicious cycle. In fact, the complicated anatomical and
functional structure of the kidney, including its uniquecells and infiltrating leukocytes. As further influx of leu-
kocytes is impaired, the number of infiltrating leukocytes vascular network, may predispose this organ to progres-
sive disease.declines in parallel to restoration of the normal architec-
ture that corresponds to the resolution of glomerulo-
nephritis in post-infectious states [13]. Whether infiltrating
THERAPEUTIC IMPLICATIONS FOR
leukocytes are mainly removed by apoptosis in situ [107]
PROGRESSIVE RENAL DISEASE
and or partially emigrate via the lymphatics or venules
Despite the somewhat conflicting experimental resultshas not been studied in detail. It is important to note
obtained with chemokine antagonists and knockout mice,that termination of the chemokine signal is critical for
specific chemokine receptors may be promising thera-the resolution of the inflammatory process. On the other
peutic targets for the use of antagonists in many inflam-hand, if local chemokine expression is augmented by
matory disease processes that involve the infiltration ofanother stimulus, a pre-existing renal disease may even-
leukocytes (Fig. 3) [110, 111]. Other families of seven-tually progress to severe renal damage. This scenario
transmembrane-spanning receptors have proven to bemay be pertinent to renin-angiotensin activation second-
valuable targets for specific therapeutic receptor blockage,ary to renal disease or to infection triggering exacerba-
for example, the -adrenergic blocker. For the blockadetion of renal disease. As noted earlier, inhibition of angio-
of the leukocytic cell infiltrate in chronic renal disease,tensin reduces renal chemokine production and leukocyte
the chemokine receptors CCR1, CCR2, CCR5, CXCR3,infiltration in both hemodynamic- and immune-mediated
and CX3CR1 should be suitable targets [13, 14, 61, 77,renal disease models [77, 90–94]. This mechanism poten-
112–114]. However, for antagonism of each of these tar-tially contributes to the proven therapeutic effects of
gets, potential systemic immunomodulatory side effectsangiotensin blockade in the progression of renal disease.
have to be carefully evaluated. Unfortunately, at presentIntercurrent infections frequently result in a deteriora-
a major problem for testing small molecule antagoniststion of renal diseases including chronic transplant ne-
is the species specificity. Most chemokine antagonistsphropathy. The proinflammatory signals of bacterial and
have been developed for the human system and unfortu-viral invasion are mediated by a group of mammalian
nately their antagonistic activity in rodents is mostly min-receptors, the Toll-like receptors-TLRs [108]. These re-
imal, precluding their testing in rodent models and ex-ceptors recognize components of the infectious agents
plaining the lack of in vivo results. Some information issuch as endotoxic lipopolysaccharides, peptidoglycanes,
available about the blockade of CCR1 during chronicand unmethylated DNA [108]. In support of such a mech-
inflammatory disease processes. Tokuda et al have devel-anism contributing to deterioration of renal disease are
oped a polyclonal antibody with blocking activity againstdata showing endotoxin-induced aggravation of experi-
CCR1 [115]. When given in the murine model of bleomy-mental GN [109]. Furthermore, we recently showed that
cin-induced pulmonary fibrosis, a marked reduction ofinjection of CpG-oligonucleotides mimicking bacterial
leukocytic cell infiltrate and interstitial fibrosis wasDNA into mice with otherwise self-limiting apoferritin-
found. We and others have found beneficial effects ofinduced glomerulonephritis resulted in a severe exacer-
bation and progression instead of resolution of the dis- CCR1 blockade with BX471, a small molecule antagonist
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Fig. 3. Mechanisms of leukocyte transmigra-
tion and possible sites for therapeutic inter-
vention. Activated endothelium expresses ad-
hesion molecules and presents chemokines on
the luminal membrane, which supports selec-
tive binding to the corresponding adhesion mol-
ecules on circulating leukocytes. Rolling of
cells and subsequent firm adhesion is followed
by spreading of the cell, which involves activa-
tion of integrins by interactions of chemokines
and their respective chemokine receptors.
Leukocyte transmigration requires temporary
disintegration of cell-cell contacts and loosen-
ing of the basement membrane, and is fol-
lowed by leukocyte migration along the che-
mokine gradient into the area of inflammation
and chemokine production. Potential sites for
chemokine antagonists as therapeutic princi-
ples include: antagonism of chemokine-medi-
ated leukocyte adhesion, activation, transmi-
gration, and migration along the chemokine
gradient. An alternative strategy would in-
volve elimination of chemokine receptor posi-
tive leukocytes by either single chain, bispec-
ific antibodies involving T cell activation or
by chemokine-cell toxin constructs.
against human and murine CCR1 on renal fibrosis in the RANTES and AOP-RANTES, two CCL5/RANTES an-
tagonists, can aggravate glomerular damage and protein-hydronephrotic kidney or in a model of rabbit renal
allograft rejection [85, 95]. Studies with other CCR1 an- uria in mice with immune complex glomerulonephritis
despite a reduction of glomerular leukocyte infiltrationtagonists using other immune-mediated disease models
(such as, collagen-induced arthritis) support the hypoth- (abstract; J Am Soc Nephrol 12:651, 2001). The variable
effects of AOP-RANTES in different models of glomer-esis that CCR1 blockade may be an effective approach
for the therapy of inflammatory disease states that in- ular injury may relate to different systemic immune
mechanisms in these models [62, 109]. Exacerbation ofvolve tissue damage by local leukocyte infiltration [115].
An additional therapeutic strategy, especially after the renal disease by targeting of single chemokine receptors
has been found also in knockout mice for the chemokineleukocyte infiltration has already occurred, could be the
targeted elimination of immune cells identified by a spe- receptors CCR1 and CCR2, as mentioned earlier in this
article [65, 66]. Although effects that occur in chemokinecific chemokine receptor. Thus, depletion of CCR5-posi-
tive T cells and monocytes is possible by bispecific single receptor knockout mice may be different from those
occurring with short-term use of receptor antagonists,chain antibodies that bind simultaneously to CCR5 on
the target cell and CD3 on T cells, thus activating the the present data indicate that therapeutic targeting of
chemokine receptors, under certain conditions, may ex-T cell to eliminate the CCR5-positive leukocytes [117].
Another possibility to eliminate CCR5 positive cells is acerbate underlying disease. The exact mechanisms of
the apparent modulatory effects of chemokine receptorsrepresented by a fusion protein consisting of the chemo-
kine CCL5/RANTES and a truncated version of Pseu- in acute renal inflammation remain to be elucidated.
Although beneficial effects of chemokine blockade atdomonas exotoxin A, which specifically destroys the tar-
get cell after binding to their CCL5/RANTES receptors present can be explained best by the prevention of leuko-
cyte infiltration, their effects on the phenotype, survivalsuch as CCR5 [117]. Elimination of leukocyte subsets
identified by a particular chemokine receptor within or immigration of infiltrated cells as well as their effects
on the overall immune response including, for example,the inflamed tissue may represent a novel therapeutic
strategy of selective immunosuppression. This approach dendritic cells, memory T cells, B cells and antibody pro-
duction, and even potential effects on renal parenchymalwould avoid systemic side effects secondary to leukope-
nia or systemic immunosuppression, but may well turn cells must be considered. Potentially the expression of
chemokine receptors on intrinsic renal cells, such asout to be limited by other unwanted reactions.
In fact, like any effective agent, chemokine antago- CCR1 and CCR7 on mesangial cells, may contribute to
unexpected effects of chemokine receptor knockoutsnists may induce adverse reactions. For example, Met-
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